Precipio (PRPO) Competitors

Accelerate Diagnostics (NASDAQ:AXDX) and Precipio (NASDAQ:PRPO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, community ranking, analyst recommendations and earnings.

Which has better earnings & valuation, AXDX or PRPO?

Precipio has higher revenue and earnings than Accelerate Diagnostics. Precipio is trading at a lower price-to-earnings ratio than Accelerate Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accelerate Diagnostics	$11.91M	2.40	-$61.62M	-$2.86	-0.40
Precipio	$17.41M	0.44	-$5.85M	-$1.83	-2.84

Do institutionals and insiders believe in AXDX or PRPO?

17.1% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 10.4% of Precipio shares are held by institutional investors. 43.6% of Accelerate Diagnostics shares are held by company insiders. Comparatively, 13.3% of Precipio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media prefer AXDX or PRPO?

In the previous week, Accelerate Diagnostics had 2 more articles in the media than Precipio. MarketBeat recorded 4 mentions for Accelerate Diagnostics and 2 mentions for Precipio. Accelerate Diagnostics' average media sentiment score of 1.25 beat Precipio's score of 0.75 indicating that Accelerate Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accelerate Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precipio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer AXDX or PRPO?

Accelerate Diagnostics presently has a consensus target price of $1.00, suggesting a potential downside of 12.27%. Given Accelerate Diagnostics' stronger consensus rating and higher probable upside, research analysts plainly believe Accelerate Diagnostics is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accelerate Diagnostics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Precipio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more risk & volatility, AXDX or PRPO?

Accelerate Diagnostics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Precipio has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

Does the MarketBeat Community favor AXDX or PRPO?

Accelerate Diagnostics received 83 more outperform votes than Precipio when rated by MarketBeat users. However, 73.32% of users gave Precipio an outperform vote while only 60.37% of users gave Accelerate Diagnostics an outperform vote.

Company	Underperform	Outperform
Accelerate Diagnostics	Outperform Votes 355 60.37%	Underperform Votes 233 39.63%
Precipio	Outperform Votes 272 73.32%	Underperform Votes 99 26.68%

Is AXDX or PRPO more profitable?

Precipio has a net margin of -17.23% compared to Accelerate Diagnostics' net margin of -471.83%. Accelerate Diagnostics' return on equity of 0.00% beat Precipio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accelerate Diagnostics	-471.83%	N/A	-191.66%
Precipio	-17.23%	-34.01%	-25.27%

Summary

Accelerate Diagnostics beats Precipio on 12 of the 19 factors compared between the two stocks.